v3.20.4
Earnings Per Common Share Attributable to Pfizer Inc. Common Shareholders (Details) - USD ($)
shares in Millions, $ in Millions
12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
EPS Numerator-Basic      
Income from continuing operations attributable to Pfizer Inc. $ 6,985 $ 10,838 $ 3,825
Less: Preferred stock dividends––net of tax 0 1 1
Income from continuing operations attributable to Pfizer Inc. common shareholders 6,984 10,837 3,824
Income from discontinued operations––net of tax 2,631 5,435 7,328
Net income attributable to Pfizer Inc. common shareholders 9,616 16,272 11,152
EPS Numerator––Diluted      
Income from continuing operations attributable to Pfizer Inc. common shareholders and assumed conversions 6,985 10,838 3,825
Income from discontinued operations––net of tax, attributable to Pfizer Inc. common shareholders and assumed conversions 2,631 5,435 7,328
Net income attributable to Pfizer Inc. common shareholders and assumed conversions $ 9,616 $ 16,273 $ 11,153
EPS Denominator      
Weighted-average number of common shares outstanding––Basic 5,555 5,569 5,872
Common-share equivalents: stock options, stock issuable under employee compensation plans convertible preferred stock and accelerated share repurchase agreements (in shares) 77 106 105
Weighted-average number of common shares outstanding––Diluted 5,632 5,675 5,977
Anti-dilutive common stock equivalents (in shares) [1] 4 2 2
[1] These common stock equivalents were outstanding for the periods presented, but were not included in the computation of diluted EPS for those periods because their inclusion would have had an anti-dilutive effect.